Capricor Therapeutics Q2 2024 GAAP EPS $(0.35) Beats $(0.36) Estimate, Sales $3.971M Beat $3.664M Estimate
Portfolio Pulse from Benzinga Newsdesk
Capricor Therapeutics (NASDAQ:CAPR) reported Q2 2024 GAAP EPS of $(0.35), beating the estimate of $(0.36). Sales were $3.971M, surpassing the $3.664M estimate and showing a 1.38% increase from the same period last year.
August 07, 2024 | 8:58 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Capricor Therapeutics reported better-than-expected Q2 2024 earnings and sales, with EPS of $(0.35) beating the $(0.36) estimate and sales of $3.971M surpassing the $3.664M estimate. Sales also increased by 1.38% year-over-year.
The better-than-expected earnings and sales figures are likely to positively impact CAPR's stock price in the short term. Beating both EPS and sales estimates generally boosts investor confidence.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100